Citalopram to Enhance Cognition in HD
NCT00271596, Phase 2, Completed, University of Iowa; results first posted 2013-03-13
Trial 12
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Citalopram to Enhance Cognition in HD | ClinicalTrials.gov |
| NCT number | NCT00271596 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Phase 2 | ClinicalTrials.gov |
| Enrollment | 33 participants, actual | ClinicalTrials.gov |
| Lead sponsor | University of Iowa | ClinicalTrials.gov |
| Conditions | Huntington Disease, Chorea, Executive Dysfunction | ClinicalTrials.gov |
| Interventions | 20mg daily citalopram, Placebo | ClinicalTrials.gov |
| First posted | 2006-01-02 | ClinicalTrials.gov |
| Last updated | 2013-03-13 | ClinicalTrials.gov |
| Results first posted | 2013-03-13 | ClinicalTrials.gov |
| Limitations and caveats | Statistical power was limited. | ClinicalTrials.gov |
Registered outcomes 10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Executive Function Composite Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort. | after 15 weeks of treatment | Full Scale Name: The Executive Composite Score (ECS). Definition: Subscales were averaged to compute this composite total score. The ECS is the weighted average of performance on 6 subtests of executive function, including (1) the Controlled Oral Word Association Test, (2) Symbol Digit Modalities test; (3) Stroop Color Word Test (Interference Trial), (4) Trail Making test (Part B), (5) Letter-Number Sequencing, and (6) Animal Naming. Construct Measured: Thinking tasks involving planning, working memory, attention, problem solving, verbal reasoning, inhibition, mental flexibility, and task switching. ECS Scale Range: The ECS score ranges from -5 to +5 on a standardized (Z) score scale, where lower scores indicate poorer performance on executive functioning tasks. Change Calculation Details: Compares change in executive functioning performance from visit 2 (week 0) to the weighted average of visits 5 (week 12) \& 6 (week 15) for the citalopram versus placebo cohort. | ClinicalTrials.gov |
| Secondary | Letter Number Sequencing Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort | after 15 weeks of treatment | Full Scale Name: Letter Number Sequencing (LNS) subtest from the Wechsler Adult Intelligence Scale (WAIS) third edition. Definition: LNS is a task that requires the reordering of an initially unordered set of letters and numbers. Construct Measured: Working memory. LNS Score Range: Raw scores may range from 0 to 21, where lower scores indicate poorer performance in working memory. Change Calculation Details: Compares change in working memory performance from visit 2 (week 0) to the weighted average of visits 5 (week 12) \& 6 (week 15) for the citalopram versus placebo cohort. | ClinicalTrials.gov |
| Secondary | Semantic Fluency Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort | after 15 weeks of treatment | Semantic Fluency Score. Definition: The Semantic Fluency Score is the number of words a person can produce given a category, including naming (1) Animal names, (2) Fruit names, (3) Boy names, (4) Girl names, and (5) Vegetable names. Construct Measured: Working memory and verbal initiation. Scale Range: The Semantic Fluency Score ranges from -5 to +5 on a standardized (Z) score scale, where lower scores indicate poorer performance on working memory tasks. Change Calculation Details: Compares change in working memory performance from visit 2 (week 0) where patients named fruit names to the weighted average of visits 5 (week 12) \& 6 (week 15) where patients named girl names and vegetable names respectively for the citalopram versus placebo cohort. | ClinicalTrials.gov |
| Secondary | Symbol-Digit Modalities Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort | after 15 weeks of treatment | Full Scale Name: The Symbol Digit Modalities Test (SDMT). Definition: The SDMT screens for organic cerebral dysfunction by having the examinee use a reference key to pair specific numbers with given geometric figures in 90 seconds. Construct Measured: Attention, processing speed, and working memory. SDMT Scale Range: Raw scores may range from 0 to 110, where lower scores indicate poorer performance. Change Calculation Details: Compares change in performance from visit 2 (week 0) to the weighted average of visits 5 (week 12) \& 6 (week 15) for the citalopram versus placebo cohort. | ClinicalTrials.gov |
| Secondary | Verbal Fluency Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort | after 15 weeks of treatment | Full Scale Name: The Verbal Fluency Score (VFC). Definition: The VFC is the number of words a person can produce given a letter, including (1) Naming words that start with F, A, and S; (2) naming words that start with K, W, and R; (3) naming words that start with V, I, and P; (4) naming words that start with O, G, and B; (5) naming words that start with E, N, and T; and (6) naming words that start with J, C, and S. Construct Measured: Verbal initiation and flexibility. Scale Range: The Verbal Fluency Composite Score ranges from -5 to +5 on a standardized (Z) score scale, where lower scores indicate poorer performance. Change Calculation Details: Compares change in verbal initiation and flexibility from visit 2 (week 0) where patients named words starting with O, G, and B to the weighted average of visits 5 (week 12) and 6 (week 15) where patients named words starting with E, N, and T, and J, C, and S respectively for the citalopram versus placebo cohort. | ClinicalTrials.gov |
| Secondary | Stroop Interference Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort | after 15 weeks of treatment | Full Scale Name: Stroop Interference subtest from The Stroop Color and Word Test. Definition: Participants are asked to name the ink color in which a word is printed when the word itself (which is irrelevant to the task) is the name of a different color rather than the same color. For example, participants may be asked to say "red" to the word blue printed in red ink. Constructs Measured: Selective attention, response inhibition, cognitive flexibility, and processing speed. Scale Range: The Stroop Interference score ranges from -5 to +5 on a standardized (Z) score scale, where lower scores indicate poorer performance. Change Calculation Details: Compares change in attention and processing speed performance from visit 2 (week 0) to the weighted average of visits 5 (week 12) and 6 (week 15) for the citalopram versus placebo cohort. | ClinicalTrials.gov |
| Secondary | Trails B Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort | after 15 weeks of treatment | Full Scale Name: Trail Making Test Part B (TMT-B). Definition: The TMT-B test requires participants to "connect-the-dots" of 25 consecutive targets on a sheet of paper where the subject alternates between numbers and letters, going in both numerical and alphabetical order. Constructs Measured: Attention, set shifting, and processing speed. Scale range: The TMT-B score ranges from -5 to +5 on a standardized (Z) score scale, where lower scores indicate poorer performance. Change Calculation Details: Compares change in attention and processing speed performance from visit 2 (week 0) to the weighted average of visits 5 (week 12) and 6 (week 15) for the citalopram versus placebo cohort. | ClinicalTrials.gov |
| Secondary | Hamilton Rating Scale for Depression Comparing Screening (Intake Visit) to Visit 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort | after 15 weeks of treatment | Full Scale Name: Hamilton Rating Scale for Depression (HAM-D). Definition: The Hamilton Rating Scale for Depression is a clinician-administered multiple item questionnaire used to provide an indication of depression. Construct Measured: Depression. HAM-D Score Range: Raw scores may range from 0 to 54, where higher scores indicate worsening mood. Change Calculation Details: Compares change in mood from screening (intake visit) to visit 6 (week 15) for the citalopram versus placebo cohort. | ClinicalTrials.gov |
| Secondary | Total Functional Capacity Score Comparing Baseline (Week -4) to Visits 4 (Week 6) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort | after 15 weeks of treatment | Full Scale Name: The Total Functional Capacity (TFC) subscale from the Unified Huntington's Disease Rating Scale (UHDRS). Definition: The TFC is a score that classifies five stages of Huntington's Disease and five levels of function in the domains of workplace, finances, domestic chores, activities of daily living and requirements for unskilled or skilled care. Construct Measured: Activities of Daily Living. Scale Range: The TFC score ranges from 0 to 13, where lower scores indicate poorer performance in activities of daily living. Change Calculation Details: Compares change in TFC performance from Baseline (week -4) to the weighted average of visits 4 (week 6) and 6 (week 15) for the citalopram versus placebo cohort. | ClinicalTrials.gov |
| Secondary | Subgroup Analysis of the Hamilton Depression Rating Scale Comparing Screening (Intake Visit) to Visit 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort | after 15 weeks of treatment | Full Scale Name: Hamilton Rating Scale for Depression (HAM-D). Definition: The Hamilton Rating Scale for Depression is a clinician-administered multiple item questionnaire used to provide an indication of depression. Construct Measured: Depression. HAM-D Score Range: Raw scores may range from 0 to 54, where higher scores indicate worsening mood. Change Calculation Details: This analysis was restricted to a subgroup and, accordingly, does not reflect the total number of participants as reported in the Participant Flow. This analysis compares change in mood from screening (intake visit) to visit 6 (week 15) for the citalopram versus placebo cohort. | ClinicalTrials.gov |
Outcomes 10
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|---|---|---|---|---|---|
| PRIMARY | Executive Function Composite Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort. | after 15 weeks of treatment | Intention to treat analysis was performed using a mixed linear model controlling for practice effects comparing visit 2 (week 0) to the weighted average of visits 5 (week 12) \& 6 (week 15) for the citalopram versus placebo cohort | units on a scale | LEAST_SQUARES_MEAN | ClinicalTrials.gov |
| SECONDARY | Letter Number Sequencing Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort | after 15 weeks of treatment | Intention to treat analysis was performed using a mixed linear model controlling for practice effects comparing visit 2 (week 0) to the weighted average of visits 5 (week 12) \& 6 (week 15) for the citalopram versus placebo cohort | units on a scale | LEAST_SQUARES_MEAN | ClinicalTrials.gov |
| SECONDARY | Semantic Fluency Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort | after 15 weeks of treatment | Intention to treat analysis was performed using a mixed linear model controlling for practice effects comparing visit 2 (week 0) to the weighted average of visits 5 (week 12) \& 6 (week 15) for the citalopram versus placebo cohort | units on a scale | LEAST_SQUARES_MEAN | ClinicalTrials.gov |
| SECONDARY | Symbol-Digit Modalities Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort | after 15 weeks of treatment | Intention to treat analysis was performed using a mixed linear model controlling for practice effects comparing visit 2 (week 0) to the weighted average of visits 5 (week 12) \& 6 (week 15) for the citalopram versus placebo cohort | units on a scale | LEAST_SQUARES_MEAN | ClinicalTrials.gov |
| SECONDARY | Verbal Fluency Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort | after 15 weeks of treatment | Intention to treat analysis was performed using a mixed linear model controlling for practice effects comparing visit 2 (week 0) to the weighted average of visits 5 (week 12) \& 6 (week 15) for the citalopram versus placebo cohort | units on a scale | LEAST_SQUARES_MEAN | ClinicalTrials.gov |
| SECONDARY | Stroop Interference Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort | after 15 weeks of treatment | Intention to treat analysis was performed using a mixed linear model controlling for practice effects comparing visit 2 (week 0) to the weighted average of visits 5 (week 12) \& 6 (week 15) for the citalopram versus placebo cohort | units on a scale | LEAST_SQUARES_MEAN | ClinicalTrials.gov |
| SECONDARY | Trails B Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort | after 15 weeks of treatment | Intention to treat analysis was performed using a mixed linear model controlling for practice effects comparing visit 2 (week 0) to the weighted average of visits 5 (week 12) \& 6 (week 15) for the citalopram versus placebo cohort | units on a scale | LEAST_SQUARES_MEAN | ClinicalTrials.gov |
| SECONDARY | Hamilton Rating Scale for Depression Comparing Screening (Intake Visit) to Visit 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort | after 15 weeks of treatment | Intention to treat analysis was performed using a mixed linear model comparing screening (intake visit) to Visit 6 (week 15) for the citalopram versus placebo cohort | units on a scale | LEAST_SQUARES_MEAN | ClinicalTrials.gov |
| SECONDARY | Total Functional Capacity Score Comparing Baseline (Week -4) to Visits 4 (Week 6) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort | after 15 weeks of treatment | Intention to treat analysis was performed using a mixed linear model comparing baseline (week -4) to the weighted average of Visits 4 (week 6) \& 6 (week 15) for the citalopram versus placebo cohort | units on a scale | LEAST_SQUARES_MEAN | ClinicalTrials.gov |
| SECONDARY | Subgroup Analysis of the Hamilton Depression Rating Scale Comparing Screening (Intake Visit) to Visit 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort | after 15 weeks of treatment | This analysis was restricted to a subgroup and, accordingly, does not reflect the total number of participants as reported in the Participant Flow. This analysis compares change in mood from screening (intake visit) to visit 6 (week 15) for the citalopram versus placebo cohort. | units on a scale | LEAST_SQUARES_MEAN | ClinicalTrials.gov |
Results by group 20
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|---|---|---|---|---|---|
| Executive Function Composite Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort. | Citalopram | 0.005 | Standard Error 0.067 | units on a scale | ClinicalTrials.gov | |
| Executive Function Composite Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort. | Placebo | 0.172 | Standard Error 0.071 | units on a scale | ClinicalTrials.gov | |
| Letter Number Sequencing Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort | Citalopram | -0.113 | Standard Error 0.113 | units on a scale | ClinicalTrials.gov | |
| Letter Number Sequencing Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort | Placebo | 0.225 | Standard Error 0.124 | units on a scale | ClinicalTrials.gov | |
| Semantic Fluency Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort | Citalopram | 0.386 | Standard Error 0.192 | units on a scale | ClinicalTrials.gov | |
| Semantic Fluency Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort | Placebo | 0.664 | Standard Error 0.187 | units on a scale | ClinicalTrials.gov | |
| Symbol-Digit Modalities Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort | Citalopram | -0.227 | Standard Error 0.113 | units on a scale | ClinicalTrials.gov | |
| Symbol-Digit Modalities Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort | Placebo | -0.170 | Standard Error 0.103 | units on a scale | ClinicalTrials.gov | |
| Verbal Fluency Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort | Citalopram | 0.140 | Standard Error 0.109 | units on a scale | ClinicalTrials.gov | |
| Verbal Fluency Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort | Placebo | 0.071 | Standard Error 0.103 | units on a scale | ClinicalTrials.gov | |
| Stroop Interference Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort | Citalopram | -0.256 | Standard Error 0.122 | units on a scale | ClinicalTrials.gov | |
| Stroop Interference Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort | Placebo | -0.046 | Standard Error 0.123 | units on a scale | ClinicalTrials.gov | |
| Trails B Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort | Citalopram | 0.087 | Standard Error 0.273 | units on a scale | ClinicalTrials.gov | |
| Trails B Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort | Placebo | 0.405 | Standard Error 0.397 | units on a scale | ClinicalTrials.gov | |
| Hamilton Rating Scale for Depression Comparing Screening (Intake Visit) to Visit 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort | Citalopram | -0.67 | Standard Error 0.76 | units on a scale | ClinicalTrials.gov | |
| Hamilton Rating Scale for Depression Comparing Screening (Intake Visit) to Visit 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort | Placebo | 1.23 | Standard Error 0.89 | units on a scale | ClinicalTrials.gov | |
| Total Functional Capacity Score Comparing Baseline (Week -4) to Visits 4 (Week 6) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort | Citalopram | -0.54 | Standard Error 0.46 | units on a scale | ClinicalTrials.gov | |
| Total Functional Capacity Score Comparing Baseline (Week -4) to Visits 4 (Week 6) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort | Placebo | -0.06 | Standard Error 0.50 | units on a scale | ClinicalTrials.gov | |
| Subgroup Analysis of the Hamilton Depression Rating Scale Comparing Screening (Intake Visit) to Visit 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort | Citalopram | -0.10 | Standard Error 0.85 | units on a scale | ClinicalTrials.gov | |
| Subgroup Analysis of the Hamilton Depression Rating Scale Comparing Screening (Intake Visit) to Visit 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort | Placebo | 1.50 | Standard Error 0.9 | units on a scale | ClinicalTrials.gov |
Participant flow 6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|---|---|---|---|---|
| Overall Study | STARTED | Citalopram | 17 | ClinicalTrials.gov | |
| Overall Study | STARTED | Placebo | 16 | ClinicalTrials.gov | |
| Overall Study | COMPLETED | Citalopram | 16 | ClinicalTrials.gov | |
| Overall Study | COMPLETED | Placebo | 15 | ClinicalTrials.gov | |
| Overall Study | NOT COMPLETED | Citalopram | 1 | ClinicalTrials.gov | |
| Overall Study | NOT COMPLETED | Placebo | 1 | ClinicalTrials.gov |
Adverse events 14
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|---|---|---|---|---|---|---|
| other | Constipation | Gastrointestinal disorders | Citalopram | 1 | 17 | 1 | ClinicalTrials.gov |
| other | Constipation | Gastrointestinal disorders | Placebo | 0 | 16 | 0 | ClinicalTrials.gov |
| other | Dry Mouth | Gastrointestinal disorders | Citalopram | 1 | 17 | 1 | ClinicalTrials.gov |
| other | Dry Mouth | Gastrointestinal disorders | Placebo | 0 | 16 | 0 | ClinicalTrials.gov |
| other | Dizziness | Nervous system disorders | Citalopram | 2 | 17 | 2 | ClinicalTrials.gov |
| other | Dizziness | Nervous system disorders | Placebo | 0 | 16 | 0 | ClinicalTrials.gov |
| other | Headache | Nervous system disorders | Citalopram | 0 | 17 | 0 | ClinicalTrials.gov |
| other | Headache | Nervous system disorders | Placebo | 1 | 16 | 1 | ClinicalTrials.gov |
| other | Ejaculation Disorder | Reproductive system and breast disorders | Citalopram | 1 | 17 | 1 | ClinicalTrials.gov |
| other | Ejaculation Disorder | Reproductive system and breast disorders | Placebo | 0 | 16 | 0 | ClinicalTrials.gov |
| other | Insomnia | General disorders | Citalopram | 1 | 17 | 1 | ClinicalTrials.gov |
| other | Insomnia | General disorders | Placebo | 2 | 16 | 2 | ClinicalTrials.gov |
| serious | worsening depression with suicidal ideation | Psychiatric disorders | Citalopram | 1 | 17 | 1 | ClinicalTrials.gov |
| serious | worsening depression with suicidal ideation | Psychiatric disorders | Placebo | 2 | 16 | 3 | ClinicalTrials.gov |
Adverse event totals 6
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|---|---|---|---|
| Total, all-cause mortality | Citalopram | ClinicalTrials.gov | ||
| Total, all-cause mortality | Placebo | ClinicalTrials.gov | ||
| Total, other adverse events | Citalopram | 6 | 17 | ClinicalTrials.gov |
| Total, other adverse events | Placebo | 3 | 16 | ClinicalTrials.gov |
| Total, serious adverse events | Citalopram | 1 | 17 | ClinicalTrials.gov |
| Total, serious adverse events | Placebo | 2 | 16 | ClinicalTrials.gov |
Papers 20
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|---|---|
| 152602 | BACKGROUND | PubMed |
| 2442679 | BACKGROUND | PubMed |
| 2445259 | BACKGROUND | PubMed |
| 8743645 | BACKGROUND | PubMed |
| 8854307 | BACKGROUND | PubMed |
| 9159735 | BACKGROUND | PubMed |
| 9222184 | BACKGROUND | PubMed |
| 9443488 | BACKGROUND | PubMed |
| 10098889 | BACKGROUND | PubMed |
| 11777733 | BACKGROUND | PubMed |
| 12354289 | BACKGROUND | PubMed |
| 12771251 | BACKGROUND | PubMed |
| 15048901 | BACKGROUND | PubMed |
| 15076012 | BACKGROUND | PubMed |
| 15377738 | BACKGROUND | PubMed |
| 15452288 | BACKGROUND | PubMed |
| 16033418 | BACKGROUND | PubMed |
| 24375941 | DERIVED | PubMed |
| 25062857 | DERIVED | PubMed |
| 26444022 | DERIVED | PubMed |
Grants 1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|---|---|---|---|---|---|
| K23NS055733 | Cognition in Clinical Trials for Huntington's Disease | BEGLINGER, LEIGH | UNIVERSITY OF IOWA | NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE | 2007 to 2011 | NIH RePORTER |
Trial comparisons 1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Citalopram vs Placebo: serious adverse events | Trial comparisons |
Tests 7
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Category Fluency | Primary outcome | ConductCognition |
| Letter-Number Sequencing Task | Primary outcome | ConductCognition |
| Stroop Color-Word Test | Primary outcome | ConductCognition |
| Symbol Coding | Primary outcome | ConductCognition |
| Task Switching Test | Primary outcome | ConductCognition |
| Trail Making Test B | Primary outcome | ConductCognition |
| Verbal Fluency | Primary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)